News

Non-immune travellers to Sub-Saharan Africa face profound risk from a malaria infection. DMG is developing a standby treatment to significantly enhance travel safety. MalaJic is a paradigm shifting innovative radical cure.

Deutsche Malaria's flagship project of developing a triple combination therapy for uncomplicated and severe Malaria is progressing to clinical trials. Deutsche Malaria is now seeking additional funding from strategic investors.

Progress in the development of Fosmidomycin-Clindamycin-Artesunate as triple combination therapy for severe malaria complicated by concomitant bacterial.

As the Company’s priority project, significant progress is being made with the preparatory work, as financed by the EU Malaria Fund, for the clinical studies that are scheduled to commence in Gabon later this year. With the prospect of a successful outcome, meeting the regulatory requirements for marketing approval in 2024, their financing is seen as an opportunity for investors.

Deutsche Malaria to receive financing to develop Fos-Clin-Art - a triple combination therapy for severe malaria.